Work packages

Lipid immunology

Deliverables

• Integration of Immune data to WP5
• Mechanistic immunology profile
• Molecular immunology profile
• Metabolic immunology profile
• Extracellular vesicle-immunology profile
• Immunology validation in clinical trials

Objectives

To provide the functional, molecular, immune-metabolic, and immuno-thrombosis dimensions to the CARE-INHEALTH atlas for the identification and validation of suitable targets to diagnose, prevent, and treat the health-to-CVD transition.

Tasks

• Functional lipid pro-resolution immune responses
• Molecular lipid pro-resolution immune responses
• Immuno-metabolism
• Immuno-thrombosis
• Harmonization of data for an integrated analysis of WP2 results and deposit in the CARE-IN-HEALTH Atlas

Epidemiology

Deliverables

• Report on personalized CVD predictors
• Replication of models across cohorts
• Epidemiology data integration to WP5

Objectives

To establish the associations of chronic non-resolving inflammation with the full continuum of the health-to-CVD transition, in three cohorts monitoring :  i) prevalent, ii) subclinical, iii) incident CVD.

Tasks

• Epidemiological associations between chronic non-resolving inflammation and dietary PUFA exposure in the transition from health to CVD
• Integration of lipidomic markers
• Replication of findings across cohorts
• Integration of data from the three cohort

Clinical trials

Deliverables

• Retrospective trial data integration in WP5
• Initiation package for RESOLVIN
• Initiation package for POMEGA-2
• Midterm recruitment report for RESOLVIN
• Midterm recruitment report POMEGA-2
• Report on posting results for RESOLVIN
• Clinical validation of the -Biosensor
• Report on posting results for POMEGA-2
• Clinical validation of the MCDSS

Objectives

The overall aim of WP4 is to retro- and prospectively determine the impact of pharmacological and dietary lipidinterventions on systemic and local lipid-driven/regulated inflammation on the health-to-CVD transition and to provide proof-of-concept for the CARE-IN-HEALTH applications.

Tasks

• Analysis and preparation of samples and a common dataset for retrospective analysis and delivery to the CARE-IN-HEALTH Atlas in WP5
• MCDSS-guided prospective clinical trial POMEGA-2
• Randomized clinical trial RESOLVIN
• Clinical validation of biosensor

Development of the CARE-IN-HEALTH Atlas and MCDSS through AI-driven data integration

Deliverables

• Data management plan
• Report on ML-based predictors
• CARE-IN-HEALTH MCDSS software
• Atlas creation
• Updated Data Management Plan

Objectives

Integrating and harmonizing data in the form of an open access user-friendly visual CARE-IN-HEALTH Atlas to be used for the development and validation of novel personalized predictive algorithms and simulation studies to assess the potential impact of the identified factors, and to develop the CARE-IN-HEALTH MCDSS.

Tasks

• Data integration and CARE-IN-HEALTH Atlas development
• Deploy ML, AI and KGE to build predictors of health-to-CVD transition
• Lipid cardiovascular immune multi-criteria digital Multi-Criteria Decision Support System
• Ascertain wide application of reliable biomarker detection methods

CARE-IN-HEALTH Biosensor development

Deliverables

• Functional biosensor prototype
• Report on CADIS App + CADIS App system
• Final biosensor performance report

Objectives

Development of CARE-IN-HEALTH Biosensor based on the CADIS integrated technology, an easy-use point-of-care interface including- the Biosensor Chip + App + ICT Platform - for multiplex molecular profiling of inflammation, multiparametric correlation and prediction of health-to-CVD transition.

Tasks

• Development of CARE-IN-HEALTH Biosensor chip for the detection of known and novel CVD biomarkers
• Proof-of-concept validation of the CARE-IN-HEALTH Biosensor for multiplex biomarker profiling in relevant cohort
• Development of the CADIS App to enable easy-user interface and biosensor chip usage in the project

Dissemination, Communication, Outreach and exploitation

Deliverables

• Plan for Dissemination, Communication & Exploitation
• Communication tools

Objectives

To disseminate the results and engage discussions with key stakeholders across Europe within the scientific community, health care professionals, public health institutes, and patient organizations

Tasks

• Internal communication
• External Communication, dissemination, and Outreach
• IP management
• Exploitation

Management and ethics

Deliverables

• Management handbook

Objectives

The overall objective of this WP is to provide efficient management and coordination of the project and the consortium and to ensure the progress of the project towards its planned objectives. WP specific objectives: 1. Provision of efficient management and administration of the project, while fulfilling all legal requirements. 2. Acting as the interface between the consortium and the EC establishing a functional management structure to ensure fruitful interaction among partners, efficient communication, and smooth reporting. 3. Providing assistance and advice to the project partners regarding administration and reporting. 4. Developing and maintaining the Data Management Plan as well as the Dissemination & Exploitation plan.

Tasks

• Project management and monitoring
• Administrative and Financial Support
• Periodic reporting
• Ethics management

Ethics requirements

Deliverables

• Ethics Advisor reports

Objectives

The objective is to ensure compliance with the 'ethics requirements' set out in this work package.

Tasks

• Project management and monitoring
• Administrative and Financial Support
• Periodic reporting
• Ethics management

Lipidomic discovery of pro-resolving effectors and markers

Deliverables

• Report on Lipidomic analysis
• Report on Immune-lipid signature panel
• Integration of lipidomics data to WP5
• Report on lipidomics in clinical trials

Objectives

To create the first complete lipidomic profiling of the inflammatory component in the health-to-CVD transition to distinguish between resolving and non-resolving inflammation. Specifically, WP1 will provide the identification of signature lipid markers to design a panel of lipids to be applied for early detection, diagnosis, risk stratification or prevention of CVD.

Tasks

• Full lipidomic profiling of selected samples
• Selection of an immune-lipid signature panel reflective of the heath-to-CVD transition
• Full scale application of the immune-lipid signature to high throughput analysis of cohort samples
• Harmonization of lipidomic results for integrated analysis and application development
• Lipidomic application in MCDSS for POMEGA-2 and RESOLVIN trials